About Us
EPS Innovative Medicine Co., Ltd. will serve as a
bridge to send
promising seeds from
both Japan and overseas to
the market
as soon as possible.
About Us
EPS Innovative Medicine (Japan) Co., Ltd. is the core company of the drug discovery and development of the healthcare business operated by EPS Creative Health Technology Group Limited.
Our business is to enhance the value of drug candidates and technologies introduced by our joint venture (JV), which is a company of our group, or those found in our research division, by combining the knowledge and know-how accumulated by EPS Group over many years and promoting clinical development on our own. We will then realize the manufacturing and launching in Japan and particularly in China or licensing them to our partner enterprises.
We will build a platform for new drug discovery and regenerative medicine and act as a “bridge” so that promising drug candidates and technologies in Japan and other countries can be delivered early not only in Japan but to the world market, particularly in Asia.
Greetings from the President
Representative Director
President and Representative Corporate Officer and CEO
Tomohiro Nakatani
Updating
Management Team
Director and Audit & Supervisory Board Member
Corporate Officers
Hiroaki Yamazaki
Corporate Officer & CAO
Updating
Masataka Haraguchi
Advisor
Updating
Tomohiro Nakatani
Representative Director President and Representative Corporate Officer and CEO
Tomohiro Nakatani started his career at Kyowa Hakko Kogyo Co., Ltd. (currently Kyowa Kirin Co., Ltd.). While working there, he started to study as a research student at the Faculty of Medicine (Epidemiology and Biostatistics School) of the University of Tokyo in 1990, and was engaged in clinical development operations in Japan and the United States. He served as the head of Biostatistics, Data Management, and Clinical Pharmacology Department, Director of Project Management Department, and Director of Development Coordination Department. He was also involved in industry activities as a member of the Steering Committee of the Drug Evaluation Committee starting in 2012 and as Chairman of the Review Board of Ethical Drug Product Information Brochure from 2017 to 2021 at Japan Pharmaceutical Manufacturers Association. He joined EPS Holdings, Inc. in 2023, concurrently serving as Representative Director President and Representative Corporate Officer and CEO of EPS Innovative Medicine (Japan) Co., Ltd. He is a pharmacist and a trial statistician certified by the Biometric Society of Japan.
Keikyo Haribayashi
Corporate Officer & CFO
Keikyo Haribayashi started his career at the financial department of Sumida Sedrin Brewery in Fujian Province, China until he resigned in 1990. From 1995 to 2001, he was engaged in finance and accounting at KPMG Peat Marwick in Japan. He moved to Sun Japan Co., Ltd. in 2001 and held the positions of Finance Manager and International Business Administration Manager. In 2016, he started to serve as Corporate Planning Manager of Corporate Management Division at Software Research Associates, Inc. In 2018, he was appointed Manager of Finance Office of EPS Holdings Co., Ltd., and in October of the same year, he joined EPS China Co., Ltd. and served as Corporate Officer and General Manager of Finance Department. Since 2022, he has concurrently served as Corporate Officer and CFO of EPS Innovative Medicine (Japan) Co., Ltd.
Tomohisa Hayakawa
Corporate Officer
Tomohisa Hayakawa was engaged in clinical development planning and project management in Japan, the U.S. and Europe at Taiho Pharmaceutical Co., Ltd. and Daiichi Pharmaceutical Co., Ltd. He joined EPS in 2007 and was in charge of project management and business development in Japan, China, and Asia. Since 2021, he has been concurrently held the position of Corporate Officer of EPS Innovative Medicine (Japan) Co., Ltd. He was appointed President and Representative Director of EPD Co., Ltd. in the same year. He has extensive experience in oncology area. He also has experience in public activities as a member of the Research Evaluation Committee of the New Energy and Industrial Technology Development Organization (NEDO) and a program committee member of the DIA Annual Conference in Japan for Asian New Drug Development, etc. He is a Ph. D in pharmacy and a pharmacist.
Toshihiko Komori
Advisor
Toshihiko Komori was engaged in research, development, and project management in several therapeutic areas including immunology, oncology, and metabolic disorders at Chugai Pharmaceutical Co., Ltd from 1983. After the company’s alliance with Roche in 2002, he was mainly in charge of project and portfolio management, early clinical development, etc. In March 2020, after the completion of his tenure as Corporate Officer, he joined EPS Holdings, Inc. as Corporation’s Advisor in October, and in 2022, he also began to serve concurrently as Advisor of EPS Innovative Medicine (Japan) Co., Ltd.
Tetsuro Yamamoto
Head of Research Center
Tetsuro Yamamoto founded a CRO for functional foods, TTC Corporation, in February 2001 and served as President and Representative Director. In 2020, he was appointed EPS Research Center Director of EPS Holdings, Inc., following the merger of his company with EPS Holdings Co., Ltd. In the meantime, he served as a visiting professor and a part-time lecturer at eight universities, including Graduate School of Medicine, The University of Tokyo. In 2005, he established TMS Co., Ltd. and served as Representative Director. In 2021, the company and Biogen Inc. in U.S. succeeded in Phase II trial for a new drug to treat acute ischemic strokes. TMS entered into an agreement with Biogen Inc. for $357 million as milestone payments and approximately 10% of expected future sales as royalty payments. In February 1999, Tetsuro Yamamoto won the first Hiratani Tamio Commemorative Awards (a study on killer toxin of Hansenula mrakii yeast). His achievement contributed significantly to the study by Kurt Wüthrich (Switzerland), a winner of Nobel Prize for Chemistry in 2002, on NMR spectroscopy for the identification of three-dimensional structure of large biological molecules. He is a PhD of engineering.